Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.45 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543579 | 0.96 | HTT (0.46) | LTA4HPPIDALDH1A1NAAAALOX5 | |
| SCHEMBL31260990 | 0.96 | EPHX2 (0.47) | LTA4HPPIDALDH1A1NAAAALOX5 | |
| SCHEMBL3105598 | 0.92 | PPID (0.47) | LTA4HPPIDALDH1A1ALOX5MAPK1 | |
| SCHEMBL2722347 | 0.88 | ALOX5 (0.53) | LTA4HPPIDALDH1A1ALOX5TSHR | |
| SCHEMBL3107232 | 0.87 | LMNA (0.47) | ALDH1A1NAAAEPHX2TSHRTDP1 | |
| SCHEMBL7572962 | 0.84 | LTA4H (0.51) | LTA4HPPIDALDH1A1NAAAEPHX2 | |
| SCHEMBL9212182 | 0.84 | ALOX5 (0.52) | LTA4HALDH1A1ALOX5EPHX2TDP1 | |
| SCHEMBL6105604 | 0.83 | ALOX5 (0.51) | LTA4HALDH1A1ALOX5EPHX2TDP1 | |
| SCHEMBL5400194 | 0.83 | ALOX5 (0.51) | LTA4HALDH1A1ALOX5EPHX2TDP1 | |
| SCHEMBL26830309 | 0.83 | LTA4H (0.49) | LTA4HPPIDALDH1A1ALOX5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642785-A1 | IL-17A MODULATORS | Usynova Pharmaceuticals Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024139171-A1 | IL-17A MODULATORS | USYNOVA PHARMACEUTICALS, LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| EP-3898587-B1 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-3898587-B1 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20220055989-A1 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | ALBERT LUDWING UNIV FREIBURG (DE) | 2022-02-24 | — | — | US | disclosed |
| US-20220055989-A1 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | ALBERT LUDWING UNIV FREIBURG (DE) | 2022-02-24 | — | — | US | disclosed |
| EP-3898587-A1 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | Albert-Ludwigs-Universität Freiburg (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127846-A9 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | ALBERT LUDWIG UNIVERSITÄT FREIBURG (DE) | 2021-08-12 | — | — | WO | disclosed |
| WO-2020127846-A9 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | ALBERT LUDWIG UNIVERSITÄT FREIBURG (DE) | 2021-08-12 | — | — | WO | disclosed |
| WO-2020127846-A1 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | ALBERT LUDWIG UNIVERSITÄT FREIBURG (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | disclosed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | disclosed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1758870-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | P2RY4, P2RX4, P2RY1 | LTA4H 1855/4885PPID 1397/4885ALDH1A1 1303/4885 |
| US-20220055989-A1 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD2 | LTA4H 3616/4885PPID 2149/4885ALDH1A1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.